Sanofi: Dupixent Late-Breaking Data From Notus Confirmatory Phase 3 COPD Study Presented at ATS and Published in NEJM
May 21, 2024
May 21, 2024
PARIS, France, May 21 (TNSres) -- Sanofi, a life sciences company, issued the following news release:
* * *
* NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation
* Data support the potential of Dupixent as the first new treatment approach . . .
* * *
* NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation
* Data support the potential of Dupixent as the first new treatment approach . . .